In this data-drenched discussion, UCSF specialists review how CAR T-cells are being used in hematologic malignancies, including aggressive lymphoma and difficult-to-treat myeloma, as well as for solid tumors, and reveal what's on the horizon with regard to these products. They discuss current options, including response rates; factors that put patients at risk for failure; and how challenges – such as transience and toxicity – may be overcome. They also look at problems with patient access that inform decision-making, including the timing of referral.
Related Presenters
Professor and Chief, Division of Hematology and Oncology
Professor and Chief, Division of Hematology and Oncology, Dept. of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, UCSF View Full Profile
Hematologist
Dr. Charalambos (Babis) Andreadis specializes in bone marrow transplantation for adults and in treating Hodgkin's and non-Hodgkin's lymphoma, leukemia and multiple myeloma. He cares for patients at the UCSF Helen Diller Family Comprehensive ...
Hematologist-oncologist
Dr. Sandy Wong is a blood disease specialist who cares for people with MGUS (monoclonal gammopathy of undetermined significance), smoldering myeloma, multiple myeloma and amyloidosis, a condition in which an abnormal protein called amyloid ...
Assistant Professor, Medicine
Dr. Carnevale is a physician-scientist who treats patients with gastrointestinal cancers, and also performs research into finding novel therapies for these diseases. View Full Profile
Related Videos
